Combination drug study for advanced pancreatic cancer after standard treatment fails
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests a new combination of two drugs (JDB153 and serplulimab) for people with advanced pancreatic cancer that has progressed after standard treatments. The goal is to see if this combo can shrink tumors or slow the cancer's growth, and to check its safety.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have pancreatic cancer that is advanced or has spread (locally advanced, unresectable, or metastatic).
- You must be between 18 and 75 years old.
- Your cancer must have grown or come back after at least one standard treatment (like chemotherapy).
- You must have at least one tumor that can be measured on a scan (CT or MRI).
- You must be in generally good health, able to care for yourself, and have adequate organ function.
- You cannot have had prior treatment with a PD-1 or PD-L1 inhibitor (immunotherapy that targets the immune system).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of chemotherapy (GnP), an immunotherapy drug (serplulimab), and targeted radiation (SBRT) as a first treatment for locally advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if this triple therapy can shrink the tumor and improve outcomes.
This trial tests a combination of chemotherapy with two newer drugs (SHR-1701 and apatinib) as the first treatment for advanced pancreatic cancer. The goal is to see if this combination is safe and effective in slowing cancer growth.
This trial tests a new drug combination for liver cancer that has progressed after standard treatment. The goal is to see if the combination can shrink tumors or slow the cancer's growth.
This trial tests a new combination of treatments for pancreatic cancer that has spread. It adds a type of immunotherapy (called serplulimab) and targeted radiation (SBRT) to the usual chemotherapy, to see if it works better than chemotherapy alone in shrinking the cancer and helping you live longer.
This trial tests a combination of chemotherapy plus two targeted drugs (serplulimab and bevacizumab) against chemotherapy alone for pancreatic cancer that cannot be removed by surgery or has spread. This approach may help shrink or stabilize the tumor longer.
This trial tests a new combination of an immunotherapy drug (QL1706) and two chemotherapy medicines (AG) as the first treatment for advanced pancreatic cancer. The goal is to see if the combination can shrink tumors and help patients live longer.
Hear when a new Refractory Pancreatic Ductal Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.